Core Insights - The high cost of advanced cell therapy drugs, reaching hundreds of thousands to millions per injection, can potentially be reduced through mRNA and advanced delivery technologies, transforming highly personalized therapies into more universal drugs [1] - The development of in vivo CAR-T therapy pipelines by Chinese biopharmaceutical companies aims to address the long development cycles and high treatment costs associated with traditional CAR-T therapies [1] Company Developments - DeepXing Biotechnology, led by Dr. Linxian Li, has innovated a delivery technology platform using lipid nanoparticles (LNP), enabling "instant modification and treatment," which could significantly lower costs and expand the range of applicable conditions for advanced immunotherapy [2] - The company has rapidly grown into an international team of over 150 people and has secured over 1 billion in financing since its establishment in late 2019 [2] Government Support - Shenzhen has initiated the 2023 second batch of special funds for strategic emerging industries, with DeepXing's LNP delivery technology platform project successfully receiving government investment [3] - The company has also received funding approval for its "R&D Investment Support Plan for Technology-based Enterprises" from the Shenzhen government [3] - DeepXing has four mRNA rare disease therapies that have received pediatric rare disease designation and orphan drug designation from the FDA [3]
深企在体内CAR-T赛道抢占先机 细胞治疗药物由定制变通用
Shen Zhen Shang Bao·2025-08-09 21:46